Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Colorectal Carcinoma: early-phase trial registry
9 of 23 indexed Metastatic Colorectal Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #724 of 28,707 conditions by registered trial count.
23 US clinical trials · 9 currently recruiting · #724 of 28,707 conditions by registered trial count
Metastatic Colorectal Carcinoma: 23 US clinical trials tracked, 9 recruiting.
Metastatic Colorectal Carcinoma is the subject of 23 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 17 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 5 of these trials.
Enrollment posture brief
Registry condition metastatic-colorectal-carcinoma
OPEN 9 | RECR 39% | LATE 1 | EARLY 17 | RANK #724 | SPON 5
Volume-matched condition peers
Nearest open-share peer: Metastatic Colorectal Cancer (39% recruiting · 46 trials)
Metastatic Colorectal Carcinoma lists 9 open slots (39% of 23 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Colorectal Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Colorectal Carcinoma recruits in line with its size-band peers.
9 of 23 indexed trials (39.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Colorectal Carcinoma research.
M.D. Anderson Cancer Center accounts for 5 of 23 trials (21.7%). 10 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Colorectal Carcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 51 among the 23 trials that report a genuine target (sentinel values excluded). 18 of those (78.3%) plan for fewer than 100 participants.
-
Metastatic Colorectal Carcinoma research is mostly interventional.
21 interventional and 2 observational studies make up this index (91.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
23 total, page 1 of 1
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
ECOG-ACRIN Cancer Research Group
NCT05863195
Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform
Mayo Clinic
NCT06349642
Intravital Microscopy in Human Solid Tumors
Mayo Clinic
NCT03823144
A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours
AstraZeneca
NCT06147037
An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response
M.D. Anderson Cancer Center
NCT04796818
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
City of Hope Medical Center
NCT04329494
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
M.D. Anderson Cancer Center
NCT04693377
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
NCT05803382
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients With Peritoneal Metastases From Colorectal Cancer
Arjun Mittra
NCT06269978
BXQ-350 in Newly Diagnosed Metastatic Colorectal Carcinoma
Bexion Pharmaceuticals
NCT05322590
Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer
National Cancer Institute (NCI)
NCT02888743
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
M.D. Anderson Cancer Center
NCT04430725
M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02595931
Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer
National Cancer Institute (NCI)
NCT02298959
SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
M.D. Anderson Cancer Center
NCT04599140
TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
Rutgers, The State University of New Jersey
NCT04294264
LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
NCT04616183
Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer
Academic and Community Cancer Research United
NCT03337087
Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
NCT03992456
Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy With FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines
National Cancer Institute (NCI)
NCT04535401
Capecitabine and Bevacizumab With or Without Atezolizumab in Treating Patients With Refractory Metastatic Colorectal Cancer
Academic and Community Cancer Research United
NCT02873195
Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
City of Hope Medical Center
NCT03317119
An Imaging Agent (I-124 M5A) in Detecting CEA-Positive Liver Metastases in Patients With Colorectal Cancer
City of Hope Medical Center
NCT03993327
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 4 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Colorectal Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Colorectal Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Colorectal Carcinoma page
23 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Metastatic Colorectal Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Metastatic Colorectal Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Colorectal Carcinoma condition card totals 23 registered trials; most-linked intervention Biospecimen Collection; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.